Xeljanz Blood Clot Lawsuit

FDA & EMA warn patients may be at risk of serious blood clots.

Studies show patients taking Xeljanz may face three to six times the risk of serious blood clots.

pfizer xeljanz lawsuit

Xeljanz Blood Clot Warnings

The FDA and European Medicines Agency recently warned that the popular arthritis and ulcerative colitis drug Xeljanz may increase the risk of serious blood clots or death. 

As a result, they recommend limited use of the drug in higher doses, in patients who are at risk of blood clots, and in those who are over the age of 65.  

The warnings were prompted by a study of the effects of Xeljanz that found higher rates of deep vein thrombosis, which are severe blood clots in the legs, and pulmonary embolism, which are dangerous blood clots in the lungs. Both can result in death. 

Xeljanz has been sold by Pfizer since 2012 with no prior warnings about the severe blood clot warnings, and experts believe thousands of patients may have been affected.

Since patients were never warned of these severe risks, they may be entitled to substantial compensation from the drug manufacturer.

Do You Qualify for a Lawsuit?

According to Pfizer, more than 200,000 patients have taken Xeljanz since it was introduced in 2012. And, with a monthly cost of around $4,500, the company made more than $1.3 billion off the drug in 2018 alone. 

Fortunately, most patients won’t be affected by blood clots
from taking Xeljanz. However, if you or a loved one were among the several hundred estimated victims, you may qualify for substantial compensation. 

Lawyers are helping patients who suffered the following after taking Xeljanz investigate and file claims against Pfizer:

  • Pulmonary embolism
  • Deep vein thrombosis (DVT)
  • Blood clots
  • Death after blood clots.

DrugNews works solely with law firms that have handled thousands of pharmaceutical drug blood clot lawsuits, and can confidentially evaluate your case at no cost. Contact us today to speak directly with a lawyer.

Free Case Review

Xeljanz Warnings & Studies

The Timeline Leading to Xeljanz Lawsuits

European Medicines Agency (EMA) officials warn that Xeljanz 10-mg twice-daily doses should not be used in most ulcerative colitis patients at risk of blood clots.
FDA issues boxed warning that patients taking the 10 mg twice-daily dose of Xeljanz or Xeljanz XR for ulcerative colitis may face higher risks of blood clots or death.
The EMA issues safety restriction advising doctors to not prescribe the Xeljanz 10 mg twice daily dose to patients at risk of blood clots.
FDA issues safety communication warning of increased risk of blood clots in the lungs and death in RA patients taking the 10 mg twice-daily dose of Xeljanz or Xeljanz XR.
FDA AERS database indicates at least 52 patients have suffered deep vein thrombosis events, 79 have experienced pulmonary embolism and 15 have died from blood clots.
FDA approves Xeljanz (tofacitinib) to treat moderate to severe active Ulcerative Colitis.
FDA approves Xeljanz (tofacitinib) and Xeljanz XR for the treatment of active psoriatic arthritis.
Xeljanz XR is approved by the FDA for the treatment of rheumatoid arthritis.
Pfizer begins selling Xeljanz after FDA approves it for treatment of rheumatoid arthritis.

Legal Rights for Blood Clot Victims

Under the laws in most states, consumers who’ve been injured by defective or dangerous products without proper warning may file lawsuits against the manufacturer. This also applies to those injured by prescription drugs.

In the past decade, lawyers have helped hundreds of thousands of victims injured by dangerous blood thinners, contraceptives and diabetes medications, and are now helping those who’ve been hospitalized or lost a family member due to blood clots from Xeljanz. 

In almost all cases, these claims are filed against the maker of the drug, and not your doctor. Additionally, these lawsuits are filed individually, instead of as part of a class action, ensuring greater compensation and legal rights for victims. 

In those situations where patients require hospital admission for pulmonary embolism or serious blood clots, and in those tragic cases of patient death, the potential compensation can be significant.

Risks of Pulmonary Embolism or DVT

According to the FDA warnings issued to date, patients facing the greatest risk of blood clots while using the 10mg twice-daily dose of Xeljanz for either ulcerative colitis or rheumatoid arthritis. 

Likewise, the EMA has warned that Xeljanz should be used “with caution” in those patients at high risk of blood clots, and that doctors shouldn’t prescribe the drug in 10mg doses or to patients over 65 unless there is no alternative treatment. 

Patients at high risk of blood clots include anyone with a history of:

  • Cancer
  • Heart attack
  • Heart failure
  • Inherited blood clot disorders
  • History of blood clots
  • Major surgery
  • Immobility
  • Obesity
  • Diabetes
  • Hypertension.

In addition, those taking combined hormonal contraceptives, hormone replacement therapies, and those who smoke may be at risk. 

Blood clots are hardened clusters of blood that the body forms naturally in order to heal wounds and repair injured blood vessels. However, they can also be caused artificially as a response to certain chemicals in prescription drugs. 

When a blood clot breaks free, it can travel through the bloodstream to the heart, lungs, brain or other organs, causing serious injury or even death. 

Pulmonary embolism occurs when a blood clot passes into the arteries of the lungs. It can block oxygen from reaching parts of the lungs, causing injury or death. Deep Vein Thrombosis (DVT) is a blood clot that forms in veins deep from the surface of the skin, often in the thigh or lower leg. 

Some common symptoms of blood clots include: redness, swelling, warmth, pain or weakness, loss of sensation in leg or arm, blood in stool.

If you’ve taken Xeljanz and experienced any of these symptoms, it is important to notify your doctor immediately.

Free Case Review

Which Xeljanz lawyer is best for your case?

If you or a family member suffered blood clots, pulmonary embolism or death, it is important to find out if your prescription medication was a factor.  

A lawyer can investigate your case, reviewing the extensive medical records that your doctor may not normally discuss. However, there’s only a limited amount of time to file a claim. 

Fortunately, it’s easy to get help and file a claim if you qualify, and you won’t pay anything unless you receive an award. Also, the right lawyer can handle most aspects of your case without you ever having to leave your home or attend court hearings.  

DrugNews makes it easy to speak directly with a lawyer or patient advocate today to learn more about your options. And, we work only with the top attorneys and law firms that have successfully handled thousands of blood clot and pulmonary embolism lawsuits against the largest companies.  

For more information, or to learn about your options - call, chat or email us today.

Do you have a case?

Speak with a lawyer who specializes in the Xeljanz litigation.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Sources of information

Get in touch with us.

Call, email or live chat with us today to see how we can help.

call DrugNews.net
Need a quick answer? Call us!
email DrugNews.net
Reach out to us by email.
live chat with DrugNews
We are here to help now